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ABSTRACT 
 
 
 The Dopamine Transporter (DAT) is a trans-membrane protein that is part of the 
SLC6 gene family. Protein Kinase C (PKC) has been shown to acutely down regulate 
DAT via membrane trafficking away from the plasma membrane. The present study was 
performed to determine the role of PKCβ, a subtype of PKC, in DAT trafficking.  
Dopamine uptake assays and cell surface protein biotinylations were performed to access 
the effect of PKCβ’s inhibition.  Wild Type DAT function and surface expression were 
not sensitive to PKCβ inhibition. In contrast, mutating DAT residues 587-589 (DAT 3A) 
revealed striking PKCβ sensitivity, resulting in significantly increased DAT function and 
surface expression following 20-minute treatment with the PKCβ inhibitor LY 379196. 
PC12 cells were subsequently discovered to be PKCβ negative. PC12 cells were then co-
transfected with PKCβ and DAT 3A to reproduce the increase in activity seen in SK-N-
MC cells, but no statistically relevant increase in DA uptake was seen. The fact that the 
increase in activity was not reproducible in PC12 cells points to an intermediary molecule 
present in SK-N-MC cells that is needed for the effect. Further experimentation is needed 
to fully characterize this effect with DAT 3A, including, but not limited to, dopamine 
internalization and recycling assays.  
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BACKGROUND 
 
 
The Dopamine Transporter (DAT) 
 The dopamine transporter (DAT) is a cell surface protein that binds dopamine, 
and has been implicated in a number of neurological disorders, including Attention 
Deficit Disorder, Bipolar Disorder, clinical depression, and addiction.  DAT is an integral 
membrane protein that functions as a symporter by pairing the movement of dopamine 
into the cell with the movement of two sodium ions and one chloride ion. The transporter 
takes advantage of the ion-gradient established by the Sodium/Potassium ATPase activity 
(Wheeler et al., 1993).  DAT belongs to the SLC6 gene family of sodium-chlorine 
dependent co-transporters. Members of the SLC6 gene family are highly homologous 
containing many of the same physical features. These transporters have 12 membrane 
spanning domains along with intracellular sites for Protein Kinase C (PKC) 
phosphorylation (Figure-1).  DAT’s function in the nervous system is to remove the 
dopamine from the synapse, terminating the signal to the post-synaptic cells. The 
dopamine cleared from the synaptic cleft is then stored intracellularly by the neuron for 
further use (Melikian, 2004).  
 
 
Figure 1: Structure of the Dopamine 
Transporter Protein DAT.  Note the 
presence of 12 transmembrane domains, and a 
cytoplasmic endocytic signal “FREKLAYAIA”.  
(Melikian, 1999) 
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 DAT has great pharmacological importance because it is the primary target of 
several addictive psycho stimulants and medical agents.  For example, cocaine is a “DAT 
blocker” that binds to the transporter preventing it from clearing dopamine (DA) out of 
the synapse, increasing synaptic dopamine and its post-synaptic signalling. 
Amphetamines (AMPH) also target the dopamine transporter, but they interact with PKC 
to modulate DA uptake. When the amphetamine binds to its receptors on the cell 
membrane it causes phosphorylation via cytoplasmic PKC.  PKC then causes a signal 
cascade that results not only in the internalization of DAT but also the efflux of dopamine 
back into the synapse. The increased dopamine concentration in the synapse is what 
causes the pleasurable feeling associated with cocaine and amphetamines. 
Methylphenidate (Ritalin) is a drug that blocks dopamine reuptake, and is used to treat 
Attention-Deficit Disorder. Many of these recreational drugs and therapeutic compounds 
are useful research tools for studying the DAT activity and trafficking (Kahhlig et al., 
2004). 
 DAT has regional distribution in the human brain, including the mesolimbic and 
mesocortical pathways of the brain. The mesolimbic pathway is known has the “reward 
pathway” because it activates behavioral responses to reward via dopaminergic 
neurotransmission (Ciliax et al., 1999).  The mesocortical pathway is associated with 
cognitive function, as well as pleasure and reward. This is also a dopaminergic pathway, 
and it connects the ventral tangentum to cerebral cortex in the frontal lobe. Dopamine has 
critical roles in behavior, movement, motivation, cognition, pleasure, memory and 
learning. It also functions as a neurohormone in the endocrine system.  DAT has a critical 
role in modulating dopamine concentrations in the brain (Marieb and Hoehn, 2007). 
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DAT Ubiquitination 
 There are two hypotheses on how the transporter is organized and recycled from 
the surface of the cell.  The fist is a model of trafficking based on ubiquitination of 
specific DAT amino acid residues. The cell tags DAT with an ubiquitin molecule to mark 
the protein for proteosomal degradation.  DAT ubiquitination increases upon PKC 
activation and begins at the cell membrane. It was revealed through DAT site directed 
mutagenesis at the amino-terminal tails that mutations of three lysine residues inhibited 
PKC-dependent ubiquitination and DAT internalization from the cell membrane 
(Miranda et al., 2007).  Several studies also suggest that the sorting of DAT between a 
recycling pathway and a proteosomal degradation pathway is also ubiquitin dependent. 
There is a correlation between PKC activation and the presence of DAT in the lysosome 
(Daniels and Amara, 1999). Following PKC activation, ubiquitinated DAT has a dramatic 
decrease in its half-life using an experimental model in which PKC activation is induced 
versus the half-life of constitutively ubiquitinated DAT (Miranda et al., 2005). There is 
strong evidence of both ubiquitin involvement in DAT degradation, and PKC 
involvement in DAT trafficking and recycling. 
 
PKC-Mediated DAT Trafficking 
 PKC-mediated DAT trafficking involves the internalization of the transporter to 
an endosome where it enters a recycling pathway. Initially, a widely accepted theory 
stated that external agents such as dopamine (DA) concentration, the presence of psycho 
stimulants, or therapeutic agents modulate DAT activity. It was discovered that the 
activation of PKC by phorbol ester PMA, and an inhibition of phosphatases caused a 
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significant down regulation in DAT activity (Pristupa et al., 1998). However, in the early 
1990s, the discovery and isolation of DAT cDNA enabled the creation of specific anti-
DAT antibodies that were utilized in DAT biochemical studies to follow its localization.  
It was shown that DAT co-localizes with TfR, an endosome marker (Figure-2, diagram 
center).  And biotin-labeled DAT on the cell surface was shown to internalize to the 
endosome following PKC activation (Melikian and Buckley, 1999), showing 
quantitatively that surface DAT was internalized based on PKC activation, and that 
diminished dopamine uptake directly resulted from DAT molecules lost from the cell 
surface. 
 
 
Figure 2 : Proposed Pathway for DAT Trafficking.  According to this model, 
DAT on the cell surface is phosphorylated by PKC, which stimulates DAT 
internalization via endosomes and its degradation via lysosomes (Melikian  and 
Buckley, 1999)  
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Constitutive DAT Trafficking 
 Subsequently it was shown that DAT undergoes both constitutive internalization 
and PKC-mediated internalization (Loder and Melikian, 2003). This was shown using 
temperature blockades to demonstrate the movement of DAT without treating the cell 
with PMA or any other PKC activator. It was shown that transferrin and DAT 
constitutively traffic via separate mechanisms based on differences in cell surface protein 
levels after treatment with bafilomycin A1, which inhibits acidification and protein 
degradation in cells (Yoshimori et al., 1991). DATs surface levels were unaffected, 
indicating that it is trafficking outside of the degradation pathway.  An important 
distinction demonstrated was that PKC-activation significantly reduces the rate of 
recycling transporter to the surface in cultured cell lines.  
 
DAT’s Conserved Endocytic Signal 
 The next step in the characterization of DAT trafficking was to determine the 
endocytic signal present in the DAT amino acid sequence that enabled the transporter to 
internalize and recycle. A gain-of-function approach was utilized to show that a chimeric 
form of DAT (containing its C-terminal end) and an interleukin 2α receptor called Tac 
was robustly internalized when exposed to PKC activating agents. The deletion of several 
amino acid residues on the C-terminus of the chimera identified the amino acid sequence 
FREKLAYAIA (shown in Figure 1) to be the endocytic signal utilized by DAT for 
internalization. Point mutations along the FREKLAYAIA sequence in WT-DAT showed 
that the LAYAIA region was necessary for DAT endocytosis. Mutation of the FREKL 
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sequence to five alanines (5A) completely abolished PKC-mediated down regulation in 
functional studies. It was also determined that the FREKLAYAIA sequence was 
conserved in all of the SLC6 transporters in mammals (Holton et al., 2005). 
 
PKCβ 
 Strong evidence implicates the role of PKC kinase in amphetamine-induced 
dopamine increases in the synapse. It was determined that specific isoforms PKCβI and 
PKCβII were responsible for the amphetamine-induced dopamine efflux in rat striatum.  
When both isoforms of PKCβ were inhibited using a specific inhibitor LY 379196, it was 
observed that the concentration of DAT on the surface of synaptosomes decreased.  
PKCβI and PKCβII were also shown to co-immunoprecipitate with DAT in complex.  
Both pieces of evidence strongly suggest an association between DAT and PKCβ 
(Johnson et al., 2005). 
 Based on the evidence discussed above, although it would be expected that a 
decrease in PKCβ would cause more DAT to remain on the surface of cells, it has been 
shown that the reverse is true. Mice with PKCβ knocked out were shown to have less 
striatal surface DAT and less dopamine (DA) uptake in synaptosomes. Tissues from WT 
and PKCβ KO mice were analyzed by DAT surface biotinylation and by a binding assay 
of a tritiated DAT antagonist. The KO mouse showed increased cell surface DAT and 
less DA efflux in response to amphetamine treatment.  A decrease in maximal uptake of 
the KO vs. WT, at varying concentrations of DA was shown. This signifies a true loss in 
the DAT surface activity and not a change in the transporter structure itself (Chen et al., 
2009).  
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PROJECT PURPOSE 
 
 This project was conducted to experimentally determine the role of PKCβ in DAT 
trafficking and activity. While previous studies in mouse synaptosomes implicated PKCβ 
in DAT activity and trafficking, further study was needed.   Characterization of the 
effects of PKCβ in cultured cells lines would help elucidate the biochemical pathway by 
which DAT trafficks.   The hypothesis tested states that PKCβ inhibition will result in a 
functional down regulation of cell surface DAT and/or transporter internalization. 
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METHODS 
 
 
 Many laboratory techniques and methods were utilized during the completion of 
this project. These procedures include cell culture and cell line maintenance, transient 
transfection, cell surface biotinylation, DA uptake assays, and immunocytochemistry.  
 
Cell Lines and Culture 
Two cell lines were utilized in this study.  SK-N-MC cells are human 
neuroblastoma.  SK-N-MC cells were cultured at 37°C, and were grown in 5% CO2.  SK-
N-MC cells contain both subtypes of PKC.  The SK-N-Mc cells were grown Minimum 
Essential Media supplemented with 5% Horse Serum and 5% Fetal Bovine Serum.  
The second cell line utilized was PC 12 cells which are a pheochromocytoma 
derived from the rat adrenal medulla.  These cells stably express DAT in the presence of 
0.2 mg/ml G418.  The PC 12 cells were cultured in DMEM supplemented with 10% Fetal 
Bovine Serum.  
 
Transfections 
SK-N-MC cells were maintained in culture as previously described.  Cells were 
plated to a density of 2.25 X 10
5
 cells per well in a 24 well Walac plate for Uptake 
Assays, and plated at a density of 1.0 X 10
6
 cells per well in a 6 well dish for 
biotinylations. Transient transfections were performed using Lipofectamine 2000 at 0.8 
g (per well of a 24-well plate) and 3 g (per well of a 6-well plate). The cells were 
transfected with a DNA lipid ratio of 2:1 in serum free Opti-MEM. The cells were 
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incubated in this Lipid/DNA/Media mixture for 4 hours, and then the medium in each 
well was changed. Cells were incubated for 48 hours post-transfection before any 
experiment was performed on them.  
PC12 cells were maintained in culture as previously described. Cells were plated 
to a density of 2.1 X 10
5
 cells per well in a 24 well scintillation plate for Uptake Assays. 
Before PC12 cells were plated on scintillation plates, the wells were washed with 0.25 
mg/ml D-polylysine, then washed with PBS to remove excess polylysine. The polylysine 
forms a layer on the bottom of each well for semi-adherent PC12 cells to stick to. The 
polylysine coating helps prevent the cells from being washed away during the washes in 
the uptake assays. PC12 cells transient transfections were performed using Lipofectamine 
2000 with 0.8 g per well of a 24-well plate. The cells were transfected with a DNA lipid 
ratio of 2:1 in serum free Opti-MEM . The cells were incubated in this Lipid/DNA/Media 
mixture for 24 hours, and then the medium in each well was changed. Cells were 
incubated for 48 hours post-transfection before any experiment was performed on them. 
 
Cell Surface Biotinylation 
SK-N-MC cells were plated at an appropriate density for each assay (well size) as 
described above.  The cells were then transfected with WT DAT plasmid in 2 wells or 
with 3A DAT in 2 wells.  The cells were incubated in vehicle or LY 379196 for 20 
minutes. The vehicle in this assay is Happy PBS
2+
; which consists of 1 mM MgCl2, 0.1 
mM CaCl, 0.2 % bovine serum albumine, 0.18 % glucose in PBS. Membrane Proteins 
were biotinylated with sulfo-NHS-SS-biotin. The cells were lysed in radioimmune 
precipitation (RIPA) buffer which contains 10 mM Tris, pH 7.4, 150 mM NaCl, 1.0 mM 
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EDTA, 0.1% SDS, 1.0% Triton X-100, and 1.0% sodium deoxycholate, and protease 
inhibitors (1.0 mM PMSF, 1.0 g/ml leupeptin, 1.0 g/ml pepstatin and 1.0 g/ml aprotinin).  
A cleared lysate was prepared by centrifugation. The protein concentration of the sample 
was determined via a BCA Protein Assay kit. Biotinylated proteins were separated from 
un-biotinylated proteins by streptavidin-agarose affinity chromatography. Protein 
presence and relative amount was then determined via SDS-PAGE and immunobloting 
for DAT.  The corresponding DAT positive bands were detected using Super Signal West 
Dura Extended Substrate. Images of the DAT positive bands were taken using a CCD 
camera gel documentation system, and were quantitated using Quantity One software 
(Bio-Rad).  
 
DA Uptake Assays 
After the incubation period for each transfection, the cells were washed three 
times with KRH buffer (120
 
mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4, 
1.2 mM KH2PO4,
 
0.18% glucose, and 10 mM HEPES, pH 7.4). Drugs for the assay were 
prepared in this KRH-glucose. The total assay volume for each well on the scintillation 
plate was 300 l. LY 379196 at a concentration of 1 M, was added to each drug-treated 
well, and the cells were allowed to incubate with the drug for the an allotted amount of 
time. At the end of the incubation period, [
3
H]DA was added to a solution containing 10 
µM pargyline and 10 µM ascorbic acid (final concentrations).  The [
3
H]DA cocktail was 
made by diluting the [
3
H]DA by 20x and filling the remaining concentration with Cold 
(nonradioactive) DA. Assays were performed in the presence of of 50 nM DMI to block
 
endogenous NE transporter activity. Non-specific counts were determined by adding 
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GBR 12909 to three wells per assay to block DAT activity. After a 10 minute incubation 
with [
3
H]DA, the cells were washed three times with ice cold KRH. The cells were then 
lysed with scintillation fluid and allowed to shake for 15 minutes. After all the cells had 
been lysed, the plate was counted in the scintillation counter.  
 
Immunocytochemistry 
PC12 cells were plated on D-polylysine-coated glass cover slips then transfected 
using the same procedure described for PC12 cell transfections. The transfected cells 
were fixed in 4% paraformaldehyde for 10 minutes. Then blocking solution was added to 
the cells and allowed to incubate for 30 minutes. The blocking solution contains 5% 
BSA, 0.2% Triton-X, 1.8% glucose, and Mouse Serum in PBS.  After the incubation 
period, the cells were treated with primary antibody against DAT (Rat Anti-DAT) 
(Chemicon) at a dilution of 1 to 2,000. The cells were allowed to sit in primary antibody 
for 1 hour. After the incubation period, the cells were washed 3 times with PBS, then 
washed three more times and allowed to shake in PBS for 5 minutes each time. The next 
step was treatment with the secondary antibody, which was Alexa594-conjugated with 
anti-Rat antibody. Light can quench the fluore in this antibody, so the plate was incubated 
for 45 minutes wrapped in tin foil. After treatment with the secondary antibody, the cells 
were washed with PBS for a final time, then allowed to dry for 30 minutes. The cover 
slips were then mounted onto slides using DAPI-Prolong Gold Mounting Media. The 
cells were allowed to dry over night before being placed on the microscope and viewed 
using fluorescent light channels on 20x objective for wide field shots, or the 63x 
objective for single cell shots.  
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RESULTS 
 
 
 
 The purpose of this project was to experimentally determine the role of PKC in 
dapamine transporter (DAT) trafficking.  Previously, PKC had been shown to co-
localize with DAT in rat striatum. When PKC was knocked out in a mouse, it decreased 
DAT’s presence on the surface of synaptosomes. Inhibiting PKC with LY379196 also 
caused a decreased surface presence of DAT on synaptosomes in mice.  The original 
hypothesis was that inhibiting PKC in cultured cells would cause a decrease in DAT 
activity as well DAT presentation on the membrane surface.  
 
Functional Studies of DAT with PKC Inhibition 
 In order to determine whether PKC is involved in DAT trafficking, dopamine 
uptake assays were performed on WT SK-N-MC cells containing normal DAT, and on 
cells transfected with a plasmid encoding a mutant DAT 3A (587-589). Changes in DA 
uptake would denote a change in DAT activity, which could be correlated with a change 
in the amount of DAT protein on the surface of the cell. In this series of experiments, 
PKC was inhibited using the PKC inhibitor LY279196. The cells were incubated in the 
presence of the inhibitor for 20, 40 and 60 minutes respectively. The assays revealed that 
PKC inhibition increases DAT (3A) activity in SK-N-MC cells (Figure-3).  The 
increase was significant at 20 minutes. 
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Figure 3: Effect of PKCβ Inhibition 
on Wild Type DAT vs. 587-590(3A) 
DAT.  PKC inhibition increased 
DAT (3A) activity in SK-N-MC cells. 
This is a graph of the percentage of Vehicle 
DA uptake over a time course.  The time 
points measured were 20, 40, and 60 
minutes of incubation with LY 379196. 
*Significantly different than Wild Type at 
same time point, p<.02, Student’s t test, n=6.  
 
  
After the increase in DAT(3A)- SK-N-MC  cells was noted, it was decided that 
assaying DAT-PC12 cells (stably expressing DAT) , which are PKC negative, would be 
a valuable control to make sure that the PKC inhibitor LY279196 drug itself is not 
having a non-specific effect beyond PKC inhibition (Figure 4).  In these cells lacking 
PKCβ, the drug treatment had no significant effect on 3A DAT or WT DAT (Figure-4). 
 
Figure 4: Effect of LY279196 
Treatment on Wild Type DAT 
vs. 587-590 (3A) DAT in PC12 
Cells Lacking PKC.  Ly279196 
had no significant effect on 3A or WT 
DAT in PC 12 cells, demonstrating the 
specificity of the drug treatment. This 
is a graph of the percentage of Vehicle 
DA uptake over a time course (20, 40, 
60 min). There was no significant 
difference at any time point between 
3A and WT DAT.  
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Cell Surface Biotinylations 
 Once it had been established that there was a significant increase in dopamine 
uptake (DAT(3A) activity) after a 20 minute incubation with a PKC inhibitor in cells 
containing PKC, the next question asked was: does the change in activity correspond to 
a change in DAT protein on the surface of the cells. The increase in transporter activity 
would lead one to believe that there would be an increase in DAT presence on the cell 
surface membrane. 
 Cell surface biotinylations were performed after a 20-minute incubation with 
LY379196 (Figure 5).  PKC inhibition caused a significant increase in the amount of 
DAT 3A at the surface of the membrane in SK-N-MC cells. A representative blot of the 
series of biotinylations is shown below (Figure-5A) along with the quantification as 
percentage of vehicle (Figure-5B) and a percentage of surface protein (Figure-5C).  
 
Figure 5A: PKC Inhibition Causes a Significant Increase in the Amount of 
DAT 3A at the Surface of the Cell Membrane in SK-N-MC Cells.  Cells were 
treated 30 min at 37°C with the indicated drug. Surface proteins were labeled by 
biotinylation.  Biotinylated (bead) and non-biotinylated (sup) proteins were separated, 
and DAT was detected as described in Materials and Methods Section.  A representative 
immunoblot is shown. 
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Figure 5B: Surface Protein as a 
Percentage of Vehicle. Average data.  
Data are expressed as % DAT on cell 
surface as compared to vehicle-treated 
cells for each construct. The LY 379196 
treated wells were incubated with the 
drug for 20 minutes and then 
biotinylated. **Significantly different 
than Wild Type, p<.002, Student’s t test, 
n=4.  
 
 
 
Figure 5C: Percent Surface DAT 
SK-N-MC. This is a graphical 
representation of the percentage of DAT 
on the surface of the cells for Vehicle 
and Drug treated conditions. The bars for 
3A show an increase in the amount of 
surface proteins for LY 379196 treated 
cells. 
 
  
 
After establishing that an increase in DAT(3A) occurred due to PKC inhibition, 
instead of a non-specific effect of the LY379196 treatment, the next experiment was 
performed to see if a phenotypic rescue could be performed in PC12 cells that are PKC-
negative.  Constructs encoding chimeric PKC1 and PKC2 fused with EGFP were co-
transfected into PC12 cells along with DAT(3A), and dopamine uptake assays were 
performed on the various conditions to see if either PKC subtype had a effect on 
transporter activity (Figure 6).  The control was DAT(3A) co-tranfected with EGFP 
vector encoding no PKC to rule out a reaction between GFP and DAT(3A).  Co-
transfection of PKC subtypes with DAT 3A in PC12 cells did not yield any effect on 
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transporter activity (Figure-6A). Immunocytochemistry was performed on the cells to 
make sure that the cells being assayed contained the PKC construct and the DAT(3A) 
construct for the experimental conditions, and the DAT(3A) and EGFP for the control 
(Figure-6B).  The immunofluoresence data showed that all transfected proteins were 
present in the cells. 
 
 
 
 
Figure 6A.  Cotransfection of PKC 
Subtypes + 3A (597-589) PC12 Cells. 
Cotransfection of PKC subtypes with DAT 3A in 
PC12 cells did not yield any effect on transporter 
activity.  Graph of uptake of PKCβ subtypes 
separately transfected with DAT 3A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.B: Immunostained DAT (3A) + 
Chimeric PKCβ.  Picture of immunostained cells to 
determine if the transfection worked for both PKCβ 
subtypes and DAT 3A.   
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DISCUSSION 
 
 
 
 The conclusions that can be drawn from these experiments are that PKC 
inhibition causes an increase in DAT(3A) activity and presentation on the membrane 
surface.  This evidence, along with the fact that DAT co-localizes with PKC, suggests 
that this subtype of PKC plays a role in DAT trafficking.  The fact that the effect seen in 
SK-N-MC cells could not be seen in the co-transfected PC12 cells lacking PKC, could 
point to a number of conclusions. The effect scene in SK-N-MC cells might require an 
intermediary molecule that is not present in PC12 cells. Also, SK-N-MC cells contain 
both subtypes of PKC so both subtypes may be required to see the effect on transporter 
activity.  
 The results are interesting when juxtaposed to past findings about PKC and its 
role in DAT trafficking.  Knocking out PKC or inhibiting it with drugs had been shown 
to decrease surface DAT levels and DAT activity in synaptosomes extracted from mice. 
In cultured cells stably expressing WT DAT, there was no change seen for DAT surface 
presentation or activity in PKC inhibited cells. Performing these experiments in a 
cultured cell line that does not normally express DAT could explain this discrepancy. The 
DAT(3A) mutant has not been tested for activity and membrane trafficking when PKC 
is inhibited in an organism. This would be a worthy future experiment to test in mice or 
rat synaptosomes, or even in cultured neurons.  
 Further study on the effect seen in DAT(3A) cultured cells is needed to fully 
characterize the nature of the effect.  Recycling and Internalizations assays are needed to 
determine if DAT(3A) is simply internalizing slower, or recycling from the endosome 
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faster.  Also, cotransfection with both subtypes of PKC plus DAT(3A) into PC12 cells 
would be a worthy experiment to see if together they would reproduce the effect seen in 
SK-N-MC cells.  
 Modulating the activity and membrane presence of DAT is very important to the 
treatment of several dopamine-related neurological disorders. The biochemical nature of 
DAT activity and trafficking must be fully characterized to be able to effectively 
modulate DAT presence and activity with therapeutic agents. The data from this MQP 
can be applied not only to help elucidate this complex biochemical pathway, but also to 
raise new questions about possible interactions between mutated forms of DAT and 
biochemical intermediaries.  
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